JAMA Ophthalmology
Randomized Controlled Trial
Brolucizumab Preserves Vision Better Than Laser in Diabetic Retinopathy
The Phase 3 CONDOR trial shows brolucizumab 6 mg maintains visual acuity and regresses disease more effectively than panretinal laser.
April 26, 2026
